IBRX ImmunityBio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IBRX

Price (delayed)

$3.72

Market cap

$2.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.05

Enterprise value

$3.02B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's equity has increased by 36% QoQ and by 3.5% YoY
ImmunityBio's quick ratio has increased by 34% YoY
ImmunityBio's net income has decreased by 15% YoY but it has increased by 3.2% QoQ
ImmunityBio's EPS has increased by 8% QoQ but it has decreased by 4% YoY
The company's gross profit fell by 6% QoQ
ImmunityBio's revenue has decreased by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.nantkwest.com/
Peers: OMGA

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
667.71M
Market cap
$2.48B
Enterprise value
$3.02B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3,334.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,437.35
Earnings
Revenue
$556,000
EBIT
-$332.35M
EBITDA
-$306.74M
Free cash flow
-$383.77M
Per share
EPS
-$1.05
Free cash flow per share
-$0.77
Book value per share
-$0.9
Revenue per share
$0
TBVPS
$0.83
Balance sheet
Total assets
$432.42M
Total liabilities
$843.06M
Debt
$717.27M
Equity
-$411.72M
Working capital
$124.76M
Liquidity
Debt to equity
-1.74
Current ratio
2.38
Quick ratio
2.13
Net debt/EBITDA
-1.76
Margins
EBITDA margin
-55,168.9%
Gross margin
100%
Net margin
-82,377.5%
Operating margin
-65,064.9%
Efficiency
Return on assets
-128.2%
Return on equity
N/A
Return on invested capital
-60.6%
Return on capital employed
-97.2%
Return on sales
-59,775.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
1.09%
1 week
-6.53%
1 month
3.33%
1 year
-34.51%
YTD
-26.63%
QTD
120.12%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$556,000
Gross profit
$556,000
Operating income
-$361.76M
Net income
-$458.02M
Gross margin
100%
Net margin
-82,377.5%
ImmunityBio's net income has decreased by 15% YoY but it has increased by 3.2% QoQ
The net margin has declined by 15% year-on-year and by 3% since the previous quarter
The company's gross profit fell by 6% QoQ
ImmunityBio's revenue has decreased by 6% QoQ

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
3,334.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,437.35
ImmunityBio's EPS has increased by 8% QoQ but it has decreased by 4% YoY
ImmunityBio's equity has increased by 36% QoQ and by 3.5% YoY
The P/S is 21% less than the 5-year quarterly average of 4153.9
ImmunityBio's revenue has decreased by 6% QoQ

Efficiency

How efficient is ImmunityBio business performance
IBRX's return on assets is down by 23% year-on-year but it is up by 9% since the previous quarter
The company's return on invested capital rose by 9% QoQ but it fell by 7% YoY
ImmunityBio's return on sales has increased by 8% YoY and by 3.3% QoQ

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 49% less than the total liabilities
The total assets has grown by 48% from the previous quarter and by 23% YoY
ImmunityBio's quick ratio has increased by 34% YoY
The company's debt to equity fell by 36% QoQ and by 4.2% YoY
ImmunityBio's equity has increased by 36% QoQ and by 3.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.